Cognex Reports Third Quarter 2026 Results

Cognex reported record Q3 2026 revenue of $313 million, up 13% year over year (19% excluding the prior-year Commercial Partnership benefit), and adjusted diluted EPS of $0.53, up 61% (89% excluding that benefit). Adjusted EBITDA margin rose 1,060 bps to 35.5%, and the company increased full-year 2026 guidance to $1.143–$1.163 billion in revenue and $1.68–$1.72 in adjusted diluted EPS. Cognex also agreed to acquire RealSense in an all-cash transaction expected to close in Q4 2026 and raised its quarterly dividend approximately 6% to $0.09 per share.

Analysis

The key earnings signal is operating leverage, but its durability is not yet proven: pricing, mix and volume helped margins while expense reductions contributed, and Q4 adjusted EBITDA margin guidance implies meaningful sequential normalization from Q3. That makes the call’s explanation of seasonality, product mix and pricing retention more important than the headline growth rate. GAAP EPS growth is especially noisy because the prior-year comparison included a large discrete tax expense; adjusted EPS and ex-partnership revenue are cleaner, though still company-defined measures.

Near term, the raised outlook supports sentiment, but a sharp opening rally could price in the improvement before investors see whether Q4 margins hold within guidance. Over 1–3 months, monitor order trends, gross margin, memory costs and any Q4 guidance refinement. Over 6–18 months, RealSense could extend Cognex into robotic perception, but acquisition value depends on product integration and customer adoption; do not capitalize the strategic narrative ahead of evidence. Cognex’s cash resources reduce financing risk, while the all-cash deal still has an opportunity cost and integration risk.

The contrarian risk is extrapolating nine quarters of margin expansion into a permanent run rate. Pricing and cost discipline may not offset future mix shifts, memory inflation or renewed investment needs. Keyence and other machine-vision suppliers could also respond on price or product breadth, limiting durable share gains. Valuation and the stock’s reaction are not provided, so upside from here cannot be assessed reliably.

Key Decisions for Investors

• Do not chase a large premarket or opening gap. Consider a staged CGNX long on post-call weakness only if management confirms broad demand and Q4 adjusted EBITDA margin remains within its stated range; the thesis is falsified by a guidance cut, weaker order commentary, or gross-margin deterioration tied to memory costs or discounting.
• On the November 5 call, prioritize Q4 sequential margin drivers, pricing retention, end-market order rates and the full-year bridge. Treat management’s broad-based growth characterization as a claim to verify against subsequent segment and customer disclosures.
• Keep RealSense as a 6–18 month catalyst, not a near-term earnings assumption. Reassess when Cognex provides deal economics, integration costs, product roadmap and evidence of customer wins; watch for acquisition-related costs or weaker-than-expected cash conversion.
• Before sizing any position, check CGNX’s current valuation and post-release price action against its own history and machine-vision peers, including Keyence. A premium that already discounts sustained high margins would weaken the risk/reward despite the improved fundamentals.